RCE Stock Overview
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom.
Recce Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.78|
|52 Week High||AU$1.38|
|52 Week Low||AU$0.74|
|1 Month Change||-13.41%|
|3 Month Change||-22.89%|
|1 Year Change||-25.48%|
|3 Year Change||252.27%|
|5 Year Change||307.90%|
|Change since IPO||158.33%|
Recent News & Updates
|RCE||AU Pharmaceuticals||AU Market|
Return vs Industry: RCE underperformed the Australian Pharmaceuticals industry which returned -17.9% over the past year.
Return vs Market: RCE underperformed the Australian Market which returned -0% over the past year.
|RCE Average Weekly Movement||6.5%|
|Pharmaceuticals Industry Average Movement||10.4%|
|Market Average Movement||9.3%|
|10% most volatile stocks in AU Market||16.3%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: RCE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: RCE's weekly volatility (6%) has been stable over the past year.
About the Company
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company’s lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective.
Recce Pharmaceuticals Fundamentals Summary
|RCE fundamental statistics|
Is RCE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RCE income statement (TTM)|
|Cost of Revenue||AU$4.25m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.048|
|Net Profit Margin||-832.73%|
How did RCE perform over the long term?See historical performance and comparison
How is Recce Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Recce Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Recce Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RCE is currently unprofitable.
Growing Profit Margin: RCE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RCE is unprofitable, and losses have increased over the past 5 years at a rate of 41.3% per year.
Accelerating Growth: Unable to compare RCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RCE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.9%).
Return on Equity
High ROE: RCE has a negative Return on Equity (-53.51%), as it is currently unprofitable.
How is Recce Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RCE's short term assets (A$16.3M) exceed its short term liabilities (A$1.1M).
Long Term Liabilities: RCE's short term assets (A$16.3M) exceed its long term liabilities (A$128.6K).
Debt to Equity History and Analysis
Debt Level: RCE has more cash than its total debt.
Reducing Debt: RCE's debt to equity ratio has reduced from 0.08% to 0% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RCE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RCE has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 29.7% each year.
What is Recce Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RCE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RCE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RCE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD1.22M) is above average for companies of similar size in the Australian market ($USD291.26K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Experienced Management: RCE's management team is considered experienced (2 years average tenure).
Experienced Board: RCE's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Recce Pharmaceuticals Ltd's employee growth, exchange listings and data sources
- Name: Recce Pharmaceuticals Ltd
- Ticker: RCE
- Exchange: ASX
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$135.267m
- Shares outstanding: 174.54m
- Website: https://www.recce.com.au
- Recce Pharmaceuticals Ltd
- Aurora Place
- Level 25
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.